-+ 0.00%
-+ 0.00%
-+ 0.00%

Arrowhead Pharmaceuticals (ARWR) Reports Weaker Full Year Results, Is The Stock Now Cheap?

Simply Wall St·11/13/2026 02:24:06
Listen to the news

Arrowhead Pharmaceuticals (ARWR) has released its full-year results, drawing investor scrutiny as revenue declined to approximately US$450.82 million, about half of the prior period, while the net loss widened to US$724.21 million compared with the previous year.

The latest figures have landed against a rough backdrop for Arrowhead Pharmaceuticals shareholders. The 1-day share price return of down 4.5% compounds a 7-day slide of 18.9% and a 90-day share price decline of 45.6%, reflecting investors reacting to weaker revenue, a sharply wider loss and the recent Argus SELL rating.

At the same time, longer history paints a different picture. The 1-year total shareholder return of 14.3% and 3-year total shareholder return of 68.0% indicate that investors who stayed through earlier volatility have still come out ahead even after the recent drop.

Recent milestones add more context for that move. Arrowhead Pharmaceuticals has refinanced its Sixth Street debt on more flexible terms, presented detailed cardiometabolic data for plozasiran and ARO-DIMER-PA at the American Heart Association meetings, and then followed up with full-year numbers that reset expectations around growth prospects and risk.

Putting this together shows a clear pattern. Short-term share price momentum is fading sharply while longer run total shareholder returns remain positive. This leaves the current US$47.15 share price caught between optimism on the pipeline and a rising focus on execution risk and funding needs.

Scan beyond Arrowhead Pharmaceuticals and stress test your biotech thesis against 29 resilient stocks with low risk scores that have held up better on risk scores as markets punish weaker earnings and balance sheets.

Arrowhead Pharmaceuticals now trades at a steep discount to both analyst targets and intrinsic value estimates after this selloff. Is that gap mispricing the cardiometabolic pipeline, or reflecting real concern about losses and funding?

Most Popular Narrative: 56% Undervalued

On the analyst consensus Narrative on Simply Wall St, Arrowhead Pharmaceuticals screens as materially undervalued, with a fair value of $107.71 set against a last close of $47.15 and a discount rate of 7.78% framing that gap.

Arrowhead Pharmaceuticals is progressing plozasiran from an initial rare disease launch toward a much larger severe hypertriglyceridemia indication, supported by around 79% to 81% triglyceride reductions and substantial acute pancreatitis risk reductions. This could materially change revenue scale if the planned supplemental U.S. filing and review translate into broader market access.

See why 15 investors see Arrowhead Pharmaceuticals as 56% undervalued.

Result: Fair Value of $107.71 (UNDERVALUED)

Still, the Arrowhead Pharmaceuticals story only holds if heavy R&D spending and interest on the US$400m term loan translate into successful late stage cardiometabolic and CNS approvals.

Find out about the key risks to this Arrowhead Pharmaceuticals narrative.

Next Steps

Sentiment on Arrowhead Pharmaceuticals is clearly split, so consider acting promptly, review the underlying data yourself and weigh both the downside and upside highlighted in the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

If Arrowhead Pharmaceuticals has your attention, do not stop there. Use this window to refresh your watchlist with fresh, high conviction ideas before the next move.